Check out an exclusive look at what we're building Junevity covered by Endpoints News Ryan Cross the Science Boss –– we're creating therapeutics for longer lifespan and healthspan by resetting cell health

Junevity emerges with $10m to ‘reset’ cells to a healthy state #longevity #investment #healthspan #biotech #reprogramming longevity.technology/news/junevity-…

This is personal to me. Five years ago, my mom fell and broke her hip. Before that, my godfather and aunt were both diagnosed with Parkinson’s. In 2020 I decided to go all in on finding new treatments for aging. I studied bioinformatics at Johns Hopkins University , did mouse brain

The Junevity RESET platform is the first to identify drug targets to reset cell health using human data, AI/ML and siRNA.

I'm hiring a Bioinformatics Data Scientist at Junevity to develop new therapeutics for longevity-related diseases. Reach out if you like transcription factors, building new ML pipelines for bio, and longer/healthier lives.

𝗡𝗘𝗪 𝗜𝗡 𝗚𝗘𝗡: Junevity co-founders Janine Sengstack & Rob Cahill share a foundational perspective on why transcription factors, once dismissed as “undruggable” and “too risky,” are now within reach thanks to advances in siRNA, omics, and AI/ML. Genetic Engineering & Biotechnology News

Longevity biotech is gearing up to deliver medicines that will capture the world’s imagination Thanks to Stifel for including Junevity as a leader in cell reprogramming

We’re excited to announce expanded Seed funding. This will help us advance JUN_01 through IND-enabling studies and into the clinic for type 2 diabetes and obesity. This could be the first siRNA cell reprogramming candidate brought to human trials. JUN_01 has demonstrated robust